NET PROFIT (x1000 DKK)
EMPLOYEES
Ascelia Pharma AB
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
9,055
|
1,624
|
2,650 |
| Earnings before taxes |
-52,037
|
-73,620
|
-88,979 |
| EBITDA |
-43,402
|
-73,794
|
-97,536 |
| Total assets |
91,522
|
58,484
|
146,055 |
| Current assets |
54,371
|
19,436
|
107,498 |
| Current liabilities |
40,251
|
8,442
|
25,070 |
| Equity capital |
51,271
|
49,924
|
120,856 |
| - share capital |
63,123
|
23,422
|
23,302 |
| Employees (average) |
11
|
23
|
22 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
56.0%
|
85.4%
|
82.7% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-47.0%
|
-123.1%
|
-59.1% |
| Current ratio |
135.1%
|
230.2%
|
428.8% |
| Return on equity (ROE) |
-101.5%
|
-147.5%
|
-73.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-12
|
1
|
2 |
| Chg. No. of employees % |
-52%
|
5%
|
10% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.